Cybin D/B/A Helus Pharma reported CAD 8.3M of revenue over the trailing twelve months, +1239% on the year before. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: CAD 8.3M (to FY2025). Net income: −CAD 113M, trailing twelve months to FY2025. Free cash flow: −CAD 69M, trailing twelve months to FY2024. Operating margin: −1627%, trailing twelve months to FY2025.

HELPCybin D/B/A Helus Pharma

Healthcare

$6.24-31% 1Y

$6.24

$3.8752 weeks$14.03

HELP as reported

Cybin D/B/A Helus Pharma reported CAD 8.3M of revenue over the trailing twelve months, +1239% on the year before. 8 reported series are charted on this page, each one as filed.

CAD 8.3M

Revenue, trailing twelve months · to FY2025 · +1239% against the twelve months before

Net income: −CAD 113M
Net income · +45% year on year · trailing twelve months to FY2025
Free cash flow: −CAD 69M
Free cash flow · trailing twelve months to FY2024
Operating margin: −1627%
Operating margin · trailing twelve months to FY2025

Details›

Every series Ryufin has for HELP, trailing twelve months
Series	Latest	Year on year	As of
Revenue	CAD 8.3M	+1239%	FY2025
Net income	−CAD 113M	+45%	FY2025
EPS	−CAD 5.59	−41%	FY2025
Operating margin	−1627%	n/a	FY2025
Net margin	−1365%	n/a	FY2025
ROE	−48%	n/a	FY2025
ROA	−44%	n/a	FY2025
Free cash flow	−CAD 69M	n/a	FY2024

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.